Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CAO Andrew Schwendenman sold 2,148 shares of the company’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $21.60, for a total transaction of $46,396.80. Following the sale, the chief accounting officer directly owned 97,277 shares in the company, valued at approximately $2,101,183.20. The trade was a 2.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Replimune Group Price Performance
REPL stock opened at $19.81 on Thursday. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $23.54. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The company has a fifty day simple moving average of $15.10 and a two-hundred day simple moving average of $10.23. The firm has a market capitalization of $1.88 billion, a P/E ratio of -7.10 and a beta of 0.93.
Replimune Group (NASDAQ:REPL – Get Free Report) last posted its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. Analysts anticipate that Replimune Group, Inc. will post -2.38 earnings per share for the current fiscal year.
Latest Replimune Group News
These are some of the REPL news items that stood out recently:
- Positive Sentiment: An earnings-call recap highlighted a rapid TUDRIQEV launch, a potentially favorable commercial development. Replimune Earnings Call Highlights Rapid TUDRIQEV Launch
- Positive Sentiment: Analysts’ consensus price target suggests 29.5% potential upside, and an upward trend in earnings-estimate revisions could support the shares. The target is not a reliable predictor on its own. Wall Street Analysts Think Replimune Group Could Surge
- Neutral Sentiment: The CEO, CFO, chief accounting officer and another insider sold a combined 82,081 shares for about $1.77 million. The sales were made to cover tax withholding tied to equity vesting; each seller retained a substantial stake. CFO SEC filing CEO SEC filing CAO SEC filing Insider SEC filing
Hedge Funds Weigh In On Replimune Group
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Replimune Group during the third quarter valued at $64,000. Allworth Financial LP purchased a new stake in Replimune Group in the second quarter worth about $62,000. Essential Partners LLC lifted its stake in Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares during the period. Legal & General Group Plc purchased a new stake in Replimune Group in the second quarter worth about $85,000. Finally, WINTON GROUP Ltd bought a new position in Replimune Group during the 2nd quarter worth about $115,000. Institutional investors own 92.53% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on REPL. Piper Sandler upped their price objective on Replimune Group from $14.00 to $27.00 and gave the company an “overweight” rating in a research report on Monday. Wall Street Zen raised Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Wolfe Research raised Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Leerink Partners increased their price target on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $18.17.
Check Out Our Latest Research Report on REPL
About Replimune Group
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Featured Articles
- Five stocks we like better than Replimune Group
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
